近日上海医药下属上药第一生化生产的缩宫素注射液及醋酸奥曲肽注射液获菲律宾药品注册证书批准上市。缩宫素用于引产等1994年在国内获批；醋酸奥曲肽用于治疗肢端肥大症等2006年国内获批、2022年通过仿制药一致性评价。两药在菲律宾上市均未额外投入研发费用仅注册费约5万元。2024年菲市场缩宫素销售额97万美元。此次获批利于拓展海外市场但受政策、汇率等因素影响销售有不确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.